Shortages of medicines in OECD countries:
Even in wealthy economies, access to medicines is increasingly affected by medicine shortages - an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the reasons for...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2022
|
| Schriftenreihe: | OECD Health Working Papers
no.137 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Even in wealthy economies, access to medicines is increasingly affected by medicine shortages - an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the reasons for this growing global problem. Although differences in monitoring mechanisms make multi-country analyses challenging, a sample of 14 OECD countries reported a 60% increase in the number of shortage notifications over the period 2017-2019. While the complexity of pharmaceutical manufacturing and supply chains hampers root cause analyses, available literature suggests that shortages, as reported by marketing authorisation holders, are predominantly due to manufacturing and quality issues. Nevertheless, commercial factors - and the policy settings that influence them - may play an important role. Although several OECD countries have implemented policy measures to mitigate, monitor and prevent shortages, more robust data and further analyses of root causes and effective policy responses are needed. The way forward should involve a global approach that engages all relevant actors and looks beyond the health care sector alone |
| Beschreibung: | 1 Online-Ressource (54 Seiten) 21 x 28cm |
| DOI: | 10.1787/b5d9e15d-en |
Internformat
MARC
| LEADER | 00000nam a22000001cb4500 | ||
|---|---|---|---|
| 001 | BV048368237 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220720s2022 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/b5d9e15d-en |2 doi | |
| 035 | |a (ZDB-13-SOC)077479513 | ||
| 035 | |a (OCoLC)1337117583 | ||
| 035 | |a (DE-599)KEP077479513 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Chapman, Suzannah |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Shortages of medicines in OECD countries |c Suzannah, Chapman, Guillaume, Dedet and Ruth, Lopert |
| 264 | 1 | |a Paris |b OECD Publishing |c 2022 | |
| 300 | |a 1 Online-Ressource (54 Seiten) |c 21 x 28cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.137 | |
| 520 | 3 | |a Even in wealthy economies, access to medicines is increasingly affected by medicine shortages - an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the reasons for this growing global problem. Although differences in monitoring mechanisms make multi-country analyses challenging, a sample of 14 OECD countries reported a 60% increase in the number of shortage notifications over the period 2017-2019. While the complexity of pharmaceutical manufacturing and supply chains hampers root cause analyses, available literature suggests that shortages, as reported by marketing authorisation holders, are predominantly due to manufacturing and quality issues. Nevertheless, commercial factors - and the policy settings that influence them - may play an important role. Although several OECD countries have implemented policy measures to mitigate, monitor and prevent shortages, more robust data and further analyses of root causes and effective policy responses are needed. The way forward should involve a global approach that engages all relevant actors and looks beyond the health care sector alone | |
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Dedet, Guillaume |4 ctb | |
| 700 | 1 | |a Lopert, Ruth |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/b5d9e15d-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033747317 | |
Datensatz im Suchindex
| _version_ | 1818896521731506176 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Chapman, Suzannah |
| author2 | Dedet, Guillaume Lopert, Ruth |
| author2_role | ctb ctb |
| author2_variant | g d gd r l rl |
| author_facet | Chapman, Suzannah Dedet, Guillaume Lopert, Ruth |
| author_role | aut |
| author_sort | Chapman, Suzannah |
| author_variant | s c sc |
| building | Verbundindex |
| bvnumber | BV048368237 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)077479513 (OCoLC)1337117583 (DE-599)KEP077479513 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/b5d9e15d-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000001cb4500</leader><controlfield tag="001">BV048368237</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220720s2022 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/b5d9e15d-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)077479513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1337117583</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP077479513</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chapman, Suzannah</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Shortages of medicines in OECD countries</subfield><subfield code="c">Suzannah, Chapman, Guillaume, Dedet and Ruth, Lopert</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (54 Seiten)</subfield><subfield code="c">21 x 28cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.137</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Even in wealthy economies, access to medicines is increasingly affected by medicine shortages - an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the reasons for this growing global problem. Although differences in monitoring mechanisms make multi-country analyses challenging, a sample of 14 OECD countries reported a 60% increase in the number of shortage notifications over the period 2017-2019. While the complexity of pharmaceutical manufacturing and supply chains hampers root cause analyses, available literature suggests that shortages, as reported by marketing authorisation holders, are predominantly due to manufacturing and quality issues. Nevertheless, commercial factors - and the policy settings that influence them - may play an important role. Although several OECD countries have implemented policy measures to mitigate, monitor and prevent shortages, more robust data and further analyses of root causes and effective policy responses are needed. The way forward should involve a global approach that engages all relevant actors and looks beyond the health care sector alone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dedet, Guillaume</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopert, Ruth</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/b5d9e15d-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033747317</subfield></datafield></record></collection> |
| id | DE-604.BV048368237 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T20:16:01Z |
| indexdate | 2024-12-19T19:01:36Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033747317 |
| oclc_num | 1337117583 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (54 Seiten) 21 x 28cm |
| psigel | ZDB-13-SOC |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Chapman, Suzannah Verfasser aut Shortages of medicines in OECD countries Suzannah, Chapman, Guillaume, Dedet and Ruth, Lopert Paris OECD Publishing 2022 1 Online-Ressource (54 Seiten) 21 x 28cm txt rdacontent c rdamedia cr rdacarrier OECD Health Working Papers no.137 Even in wealthy economies, access to medicines is increasingly affected by medicine shortages - an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the reasons for this growing global problem. Although differences in monitoring mechanisms make multi-country analyses challenging, a sample of 14 OECD countries reported a 60% increase in the number of shortage notifications over the period 2017-2019. While the complexity of pharmaceutical manufacturing and supply chains hampers root cause analyses, available literature suggests that shortages, as reported by marketing authorisation holders, are predominantly due to manufacturing and quality issues. Nevertheless, commercial factors - and the policy settings that influence them - may play an important role. Although several OECD countries have implemented policy measures to mitigate, monitor and prevent shortages, more robust data and further analyses of root causes and effective policy responses are needed. The way forward should involve a global approach that engages all relevant actors and looks beyond the health care sector alone Social Issues/Migration/Health Dedet, Guillaume ctb Lopert, Ruth ctb https://doi.org/10.1787/b5d9e15d-en Verlag kostenfrei Volltext |
| spellingShingle | Chapman, Suzannah Shortages of medicines in OECD countries Social Issues/Migration/Health |
| title | Shortages of medicines in OECD countries |
| title_auth | Shortages of medicines in OECD countries |
| title_exact_search | Shortages of medicines in OECD countries |
| title_exact_search_txtP | Shortages of medicines in OECD countries |
| title_full | Shortages of medicines in OECD countries Suzannah, Chapman, Guillaume, Dedet and Ruth, Lopert |
| title_fullStr | Shortages of medicines in OECD countries Suzannah, Chapman, Guillaume, Dedet and Ruth, Lopert |
| title_full_unstemmed | Shortages of medicines in OECD countries Suzannah, Chapman, Guillaume, Dedet and Ruth, Lopert |
| title_short | Shortages of medicines in OECD countries |
| title_sort | shortages of medicines in oecd countries |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/b5d9e15d-en |
| work_keys_str_mv | AT chapmansuzannah shortagesofmedicinesinoecdcountries AT dedetguillaume shortagesofmedicinesinoecdcountries AT lopertruth shortagesofmedicinesinoecdcountries |